FDA grant fast track designation for tozuleristide for peadiatric central nervous system tumours

Currently phase 2/3 pivotal trials are ongoing for use of this tumour-targeting optical imaging agent which helps visualisation of cancer cells during surgery (which can potentially improve surgical precision and tissue sparing during the procedure).

Source:

Biospace Inc.